Insys Therapeutics, Inc. (INSY) Shares Bought by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC increased its holdings in Insys Therapeutics, Inc. (NASDAQ:INSY) by 3.6% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 64,048 shares of the specialty pharmaceutical company’s stock after buying an additional 2,250 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.09% of Insys Therapeutics worth $810,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in INSY. Alliancebernstein L.P. increased its holdings in Insys Therapeutics by 128.6% in the 2nd quarter. Alliancebernstein L.P. now owns 140,840 shares of the specialty pharmaceutical company’s stock worth $1,782,000 after buying an additional 79,220 shares in the last quarter. Strs Ohio grew its stake in shares of Insys Therapeutics by 40.0% during the 2nd quarter. Strs Ohio now owns 175,000 shares of the specialty pharmaceutical company’s stock valued at $2,213,000 after purchasing an additional 50,000 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Insys Therapeutics during the 2nd quarter valued at about $612,000. Geode Capital Management LLC grew its stake in shares of Insys Therapeutics by 9.7% during the 1st quarter. Geode Capital Management LLC now owns 305,044 shares of the specialty pharmaceutical company’s stock valued at $3,206,000 after purchasing an additional 26,913 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in shares of Insys Therapeutics during the 2nd quarter valued at about $240,000. Institutional investors own 25.23% of the company’s stock.

A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. TheStreet downgraded Insys Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, August 21st. BidaskClub downgraded Insys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Royal Bank Of Canada cut their price target on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insys Therapeutics in a research note on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $9.38.

COPYRIGHT VIOLATION NOTICE: “Insys Therapeutics, Inc. (INSY) Shares Bought by TIAA CREF Investment Management LLC” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/13/insys-therapeutics-inc-insy-shares-bought-by-tiaa-cref-investment-management-llc.html.

Insys Therapeutics, Inc. (NASDAQ INSY) opened at $5.16 on Monday. Insys Therapeutics, Inc. has a 12-month low of $4.10 and a 12-month high of $15.02.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply